

This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1. (Currently amended) A method for the introduction of the production of TGF- β 1 and of the expression of TGF- β 1 in and/or on Treg cells comprising utilizing ~~Use of~~ one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the induction of the production of TGF- β 1 and of the expression of TGF- β 1 in and/or on Treg cells.
2. (Currently amended) The ~~use~~ method according to claim 1, wherein the one inhibitor or the several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity is/are at least one member selected from the group consisting of actinonin, leuhistin, phebestin, amastatin, bestatin, probestin, arphamenin, MR 387, β -amino thiols, α -amino phosphinic acids and their esters and their salts, α -amino phosphonats, α -amino boronic acids, α -amino aldehydes, hydroxamates of α -amino acids, N-phenyl phthalimides, N-phenyl homophthalimides, α -ketoamides, thalidomide and its derivatives.
3. (Currently amended) The ~~use~~ method according to claim 2, wherein, as the one inhibitor or the several inhibitors, α -ketoamides, preferably 3-amino-2-oxo-4-phenylbutanoic acid amides, α -amino phosphinic acids, preferably D-Phe- γ [PO(OH)-CH₂]-Phe-Phe, N-phenyl

homophthalimides, preferably PAQ-22, α -amino phosphonates, preferably RB3014 and/or phebestin, particularly preferably PAQ-22, RB3014 and/or phebestin is/are used.

4. (Currently amended) The ~~use~~ method according to ~~any~~ ~~of the claims 1 to 3~~, wherein cytosolic alanyl aminopeptidase serves as the enzyme having a similar substrate specificity.
5. (Currently amended) The ~~use~~ method according to claim 4, wherein PAQ-22 is used as the one inhibitor or wherein the several inhibitors comprise PAQ-22.
6. (Currently amended) ~~Use of~~ A method for preventing and/or treating autoimmune diseases comprising utilizing one inhibitor or of several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for preventing and/or treating autoimmune diseases.
7. (Currently amended) The ~~use~~ method according to claim 6 for preventing and/or treating rheumatoid arthritis, Lupus Erythematoses, multiple sclerosis, IDDM, Morbus Crohn, Colitis Ulcerosa, psoriasis, neurodermatosis, glomerulonephritis, interstitial nephritis, vasculitis, autoimmune diseases of the thyroid gland, autoimmune hemolytic anemia or other chronic diseases having an inflammatory genesis as, for example, arteriosclerosis.
8. Cancelled.

9. (Currently amended) ~~Use of~~ A method for preventing and/or treating allergies comprising utilizing one inhibitor or of several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for preventing and/or treating allergies of the type I (according to Gell and Coombs), hay fever or allergies of the type II, III or IV.
10. Cancelled.
11. ~~Use of~~ A method for suppressing graft rejections comprising utilizing one inhibitor or of several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for suppressing graft rejection reactions.
12. Cancelled.
13. Cancelled.
14. Cancelled.
15. Cancelled.
16. Cancelled.
17. (Currently amended) The ~~use~~ method according to ~~any of the claims 1 to 16~~, wherein peptide fragments of pathogenic autoantigens or synthetic analogs and/or specific antigenic components of pathogenic microorganisms are used in addition.
18. Cancelled.

19. Cancelled.
20. (Currently amended) ~~Use of~~ A medicament or pharmaceutical preparation method comprising utilizing one inhibitor or ~~of~~ several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical preparation for the induction of the production of TGF- β 1 and of the expression of TGF- β 1 in and/or on Treg cells.
21. Cancelled.
22. Cancelled.
23. Cancelled.
24. Cancelled.
25. (Currently amended) ~~Use of~~ A medicament or pharmaceutical preparation method comprising utilizing one inhibitor or ~~of~~ several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical preparation for preventing and/or treating autoimmune diseases.
26. Cancelled.
27. Cancelled.
28. (Currently amended) ~~Use of~~ A medicament or pharmaceutical composition preparation method comprising utilizing one inhibitor or ~~of~~ several inhibitors of alanyl aminopeptidases and/or of enzymes

having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical composition for preventing and/or treating allergies of the type I (according to Gell and Coombs), hay fever or allergies of the type II, III or IV.

29. Cancelled.

30. (Currently amended) ~~Use of~~ A medicament or pharmaceutical preparation method comprising utilizing one inhibitor or ~~of~~ several inhibitors of alanyl aminopeptidases and or of enzymes having a similar substrate specificity for the preparation of a medicament or of a pharmaceutical preparation for suppressing graft rejection reactions.

31. Cancelled.

32. Cancelled.

33. Cancelled.

34. Cancelled.

35. Cancelled.

36. Cancelled.

37. Cancelled.

38. Cancelled.


39. (Original) Pharmaceutical preparation, comprising one inhibitor or of several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity as well as one or several

pharmacologically unobjectionable carrier, additive and/or auxiliary substance(s).

40. (Original) Pharmaceutical preparation, comprising one inhibitor or several inhibitors of alanyl aminopeptidases and/or of enzymes having a similar substrate specificity and peptide fragments of pathogenic autoantigens or synthetic analogs and/or specific antigenic components of pathogenic microorganisms as well as one or several pharmacologically unobjectionable carrier, additive and/or auxiliary substance(s).

Respectfully submitted,

By:



Martin G. Linihan

Reg. No. 24,926

HODGSON RUSS LLP
One M&T Plaza, Suite 2000
Buffalo, New York 14203
Telephone: 716-848-1367
Dated: December 29, 2004